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Abstract
Background: Compromised physiological reserve, comorbidities, and the natural history of pancreatic cancer may
deny pancreatic resection from elderly patients. We evaluated outcomes of elderly patients amenable to pancreatic
surgery.
Methods: The medical records of all patients who underwent pancreatic resection at our institution (1995-2007)
were retrospectively reviewed. Patient, tumor, and outcomes characteristics in elderly patients aged ≥ 70 years
were compared to a younger cohort (<70y).
Results: Of 460 patients who had surgery for pancreatic neoplasm, 166 (36%) aged ≥ 70y. Compared to patients
< 70y (n = 294), elderly patients had more associated comorbidities; 72% vs. 43% (p = 0.01) and a higher rate of
malignant pathologies; 73% vs. 59% (p = 0.002). Operative time and blood products consumption were
comparable; however, elderly patients had more post-operative complications (41% vs. 29%; p = 0.01), longer
hospital stay (26.2 vs. 19.7 days; p < 0.0001), and a higher incidence of peri-operative mortality (5.4% vs. 1.4%;
p = 0.01). Multivariable analysis identified age ≥ 70y as an independent predictor of shorter disease-specific survival
(DSS) among patients who had surgery for pancreatic adenocarcinoma (n = 224). Median DSS for patients aged
≥ 70y vs. < 70y were 15 months (SE: 1.6) vs. 20 months (SE: 3.4), respectively (p = 0.05). One, two, and 5-Y DSS
rates for the cohort of elderly patients were 58%, 36% and 23%, respectively.
Conclusions: Properly selected elderly patients can undergo pancreatic resection with acceptable post-operative
morbidity and mortality rates. Long term survival is achievable even in the presence of adenocarcinoma and
therefore surgery should be seriously considered in these patients.
Introduction
Pancreatic cancer is the fourth leading cause of cancer
related mortality in the U.S. with an estimated five-year
survival of about 5% reflecting the aggressive nature of
this disease [1]. In spite of recent advances in the fields
of medical oncology and radiation, and the common use
of neo-adjuvant and/or adjuvant systemic chemotherapy
complete resection (R0) is the single most important
factor determining outcome [2,3]. Unfortunately, the
majority of patients are deemed unresectable at the time
of diagnosis due to distant metastasis or a locally exten-
sive disease [3]. Historically, peri-operative mortality and
post-operative complications rates following pancreatic
surgery were unacceptable [4]; however, during the last
two decades surgical outcome significantly improved
with reported data showing a peri-operative mortality
rate of less than 2% in high volume centers [5,6]. Never-
theless, pancreatic surgery is still widely considered as a
complex procedure which is associated with consider-
able morbidity and mortality [7] and therefore clinicians
still fail to refer patients with early stage pancreatic
cancer to surgery [8].
As a result of demographic changes in developed
countries, the proportion of the elderly population is
rapidly increasing; by 2025, 20% of Americans will be
65 years or older as compared with 12% of the current
population [9]. Since the incidence of cancer increases
with aging, the burden of cancer is likely to increase as
well [10]; consequently, the number of elderly patients
diagnosed and treated for pancreatic cancer is also
expected to increase. The rising number of elderly
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dilemma for gastroenterologists, medical oncologists,
and surgeons who might hesitate to treat these patients
in a comparably manner as used for younger patients
due to factors such as decreased performance status,
associated comorbidities, and the natural history of the
disease.
Over the last decade several reports described out-
come for pancreatic surgery in elderly patients
[4,6,11-15]; however, results are inconsistent. We uti-
lized a relatively large database of 475 pancreatectomies,
seeking to evaluate early and late surgical outcome in
elderly pancreatic cancer patients; in addition, we exam-
ined whether age per-se is a risk factor for adenocarci-
noma-specific mortality following complete resection.
Methods
The study was approved by our institutional review
board; a waiver of consent was granted for the proposed
patient record review. The medical records of all
patients (n = 475) who had surgery for pancreatic neo-
plasm from January 1995 to April 2007 were evaluated.
Patients with metastatic disease and/or incomplete data
were excluded (n = 15); 460 patients were included in
the study cohort. All patients remained in active clinical
follow-up through our out-patient clinic.
Evaluation methods for clinical determinations of
interest included various radiographic (CT, MRI, PET,
US, etc.) and clinical examinations. Some patients were
treated with systemic chemotherapy and/or radiation in
accordance with the physician recommendations of the
multidisciplinary planning conference. The recommen-
dations for surgical, chemotherapeutic, and radiation
treatments were based on an evaluation of clinical prog-
nostic factors.
Clinical, imaging and pathological data of all patients
were retrospectively reviewed. Outcomes were compared
between two patients groups according to age: under
70 years (n = 294) vs. 70 years or older (n = 166) and
the type of operation performed: Pancreaticoduodenect-
omy (PD) vs. other pancreatectomies (Distal subtotal
pancreatectomy, total pancreatectomy and enucleation).
Surgical technique was standardized with systematic
lymphadenectomy, patients who had partial resection of
superior mesenteric vein and/or portal vein were
included in the study cohort. None of the elderly
patients included in the study cohort had pyloric preser-
vation PD; the vast majority of the younger cohort had
their pylorus preserved.
Demographic characteristics, comorbidities, intrao-
perative data, pathologic data, perioperative morbidity,
perioperative mortality (30-day) and survival were com-
pared between both age groups.
The following preoperative clinicopathological features
were included in the analysis: gender, age, clinical pre-
sentation, and imaging findings. All patients were evalu-
ated by imaging studies prior to surgery including
ultrasound (US), computed tomography (CT) and endo-
scopic ultrasound (EUS). Endoscopic retrograde cholan-
giopancreaticography (ERCP) was performed in the
minority of patients with pancreatic head tumors,
usually as a draining procedure. Associated comorbid-
ities were documented and categorized as ischemic
heart disease, diabetes Melitus, hypertension, CVA/TIA,
second primary malignancies, and others. Intraoperative
findings that were evaluated included type of pancreatic
resection, tumor location, tumor size, number of packed
cells (PC) units consumed and length of operation.
Overall incidence of postoperative complications was
reviewed; the following peri-operative complications
were documented and included in the present analysis:
massive post-operative bleeding, septic complications,
renal failure, pancreatic fistula, thromboembolic event,
and evisceration. Pancreatic fistula was documented in
the occurrence of >30 ml amylase rich fluid from drains
on postoperative day seven or upon discharge with sur-
gical drains in place regardless of the amount. All other
complications were categorized as others. Peri-operative
mortality was defined as in-hospital death within
30 days after surgery. Data concerning microscopic mar-
gins of resection, histological type, tumor grade, and
lymph node involvement were obtained from the patho-
logical reports.
Statistical analysis
The endpoint of this study was disease- specific survi-
val. Disease-specific survival (DSS) was calculated as
the elapsed time from operation at our institution to
death from disease; data were censored at time of last
follow-up.
Patients who died from other causes or unknown
causes were included in the DSS analysis as censored
cases. Kaplan-Meier [16] curves were constructed to
determine DSS time. The log-rank test [17] was used to
compare DSS between subgroups of patients. Compari-
son between patient groups with regard to demo-
graphics and clinical variables was performed using
Mann-Whitney and Chi-square test as applicable. All
values are expressed as mean ± SD for parametric and
median for non parametric variables. Univariable Cox
[18] proportional hazards regression models were exam-
ined to assess the ability of patient characteristics to
predict DSS. A multivariable Cox model was performed
using backward elimination with p-value cutoff of 0.05.
All computations were carried out in SPSS for windows
software version 17.0.
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Patient and tumor characteristics
One hundred and sixty-six patients (36%) over the age
of 70 years who had surgery for pancreatic neoplasm at
our institution were identified and are included in the
elderly study cohort. Patients and tumor characteristics
are depicted in Table 1. The median age at the time of
presentation to our institution was 75 years (range,
70-87); there were 64 men (39%) and 102 women (61%).
One hundred and ten patients (66%) had associated
comordities with an American Society of Anesthesiolo-
gists (ASA) score of 3, 10 patients (6%) were categorized
as ASA score 4; cardiovascular comorbidities (ischemic
heart disease, previous myocardial infarction, hyperten-
sion, and previous cerebrovascular accident) accounted
for 87% of the total documented conditions, whereas
significant respiratory or renal insufficienty accounted
for less than 10%. One hundred and fifty-eight patients
(95%) had surgery for malignant or potentially malignant
tumors (e.g., Intra ductal papillay mucinous tumor).
Table 1 Clinical and pathological data
All patients
N = 460
<70 years
N = 294
≥70 years
N = 166
P value
Age, years, median (range) 65 (19-87) 55 (19-69) 75 (70-87) <0.0001
Gender
Male (%) 214 (47%) 150 (51%) 64 (39%) 0.01
Female (%) 246 (53%) 144 (49%) 102 (61%)
ASA* score
1/2 195 (42%) 156 (53%) 39 (24%) 0.002
≥ 3 246 (53%) 126 (43%) 120 (72%)
Unknown 19 (5%) 12 (4%) 7 (4%)
Second primary cancer (per history) 51 (11%) 25 (9%) 26 (16%) 0.02
Jaundice 160 (35%) 83 (28%) 77 (46%) <0.0001
Diagnostic evaluation
Tomography 443 (96%) 285 (97%) 158 (95%) 0.5
Ultrasound 149 (32%) 99 (34%) 50 (30%) 0.37
Endoscopic ultrasound 291 (63%) 197 (67%) 94 (67%) 0.73
ERCP** 140 (30%) 85 (29%) 55 (33%) 0.21
Preoperative anemia (Hgb < 11 g/dL) 38 (8%) 17 (6%) 21 (13%) 0.12
Tumor site
Head 297 (65%) 173 (59%) 124 (73%) 0.004
Body/tail 163 (35%) 121 (41%) 42 (27%)
Invasive cancer 293 (64%) 173 (59%) 121 (73%) 0.002
Histology
Ductal adenocarcinoma 180 (39%) 105 (36%) 75 (45%) 0.2
Papillary carcinoma 44 (10%) 24 (8%) 20 (12%) 0.41
Cholangiocarcinoma 20 (4%) 14 (5%) 6 (4%) 0.38
IPMN 47(10%) 25 (9%) 22 (13%) 0.16
MCN 53 (12%) 35 (12%) 18 (11%) 0.36
NET 33 (7%) 28 (10%) 5 (3%) 0.009
Others 83 (18%) 63 (20%) 20 (12%) 0.1
*ASA- American society of anesthesiologists; **ERCP- Endoscopic retrograde cholangiopancreatography.
Lahat et al. World Journal of Surgical Oncology 2011, 9:10
http://www.wjso.com/content/9/1/10
Page 3 of 8One hundred and twenty-four tumors (73%) were
located in the head of the pancreas, and the most com-
mon histology was pancreatic ductal adenocarcinoma
(45%, n = 75).
Treatment characteristics
All 166 patients included in the study cohort had com-
plete macroscopic resection at our institution. Table 2
depicts treatment rendered. One hundred and twenty
patients (72%) had pancreaticoduodenectomy (PD), 42
(25%) underwent distal pancreatectomy, two (1.5%)
patients had total pancreatectomy, and two (1.5%) had
their tumors enucleated. Vascular resections were per-
formed in three cases. Mean operative time for patients
who had PD and distal pancreatectomy was 318 minutes
(SE: 67) and 179 minutes (SE: 80), respectively. Mean
number of packed cells units consumed during surgery
for the entire cohort was 1.74 (SE: 2.2); 104 patients
(63%) did not receive blood products during their opera-
tion. Microscopic margins were negative in 95% of
malignant tumor cases (n = 158). 25 patients (15%)
received systemic chemotherapy in conjunction with
surgery, the vast majority (92%; n = 23) in the post-
operative setting.
Early post-operative outcome
There were no cases of intra-operative deaths; mean
post-operative stay for patients who underwent PD and
distal pancreatectomy was 28.2 days (SE: 15.3) and 18.7
days (SE: 11.7), respectively. The 30-day post-operative
mortality rate for the entire cohort was 5.4% (n = 9); 8
out of 120 patients (6.6%) had PD, one out of 43 patients
underwent distal pancreatectomy (2.3%). Five patients
developed multi organ failure following septic complica-
tions, three died due to pulmonary embolism, and one
due to hemorrhagic shock followed by acute myocardial
infarction and multi organ failure. Overall complication
rate was 41% (n = 68); 28 (17%) of them were defined as
medical, whereas 40 (24%) were surgical. The most com-
mon were septic complications (31.3%; n = 52), 18 (11%)
of these patients were diagnosed with pneumonia; pan-
creatic fistula (12%; n = 20). Most surgical complications
were approached in a conservative manner; however,
10 patients (6%) underwent re-operation, mostly due to
post-operative bleeding (n = 6).
Long-term outcome
All patients were followed in the out patient clinic at our
institution and the median follow-up interval for the
entire cohort and for the subset of survivors was 22
months (range, 1-187) and 41.5 months (range, 3-187),
respectively. Overall, 92 patients (55.4%) died of disease;
Kaplan-Meier survival analysis was performed for the
entire cohort and for patients treated for pancreatic ade-
nocarcinoma, separately. The estimated median survival
for the entire cohort was 27 months (95% CI: 17-43) with
1-, 2-, and 5-year DSS rate of 67% (SE: 2), 52% (SE: 2.4),
and 40% (SE: 2.7), respectively (Figure 1A). The estimated
median survival for the sub-cohort of elderly patients
who were surgically treated for pancreatic adenocarci-
noma (n = 75) was 15 months (95% CI: 12.5-26.5) with
1-, 2- and 5-year DSS rate of 58% (SE: 3.1), 36% (SE: 3.6),
and 23% (SE: 3.7), respectively (Figure 1B).
Evaluating whether age ≥ 70 years is a risk factor for
shorter DSS, we performed univariable Cox regression
analyses for all patients who had surgery for pancreatic
Table 2 Treatment characteristics
All patients
N = 460
<70 years
N = 294
≥70 years
N = 166
P value
Surgery
Pancreaticoduodenectomy (PD) 293 (64%) 173 (59%) 120 (72%) 0.004
Distal pancreatectomy 147 (32%) 105 (35%) 42 (25%) 0.03
Total pancreatectomy 16 (2%) 14 (5%) 2 (1.5%) 0.05
Enucleation 4 (1%) 2 (1%) 2 (1.5%) 0.29
Mean operative time (minutes)*
PD 282 (SE:72) 268 (SE:55) 318 (SE:67) 0.07
Distal pancreatectomy 160 (SE:97) 155 (SE:92) 179 (SE:80) 0.13
Intra-operative PC** consumption
Mean (# PC units) 1.72 (SE:2.5) 1.69 (SE:1.7) 1.74 (SE:2.2) 0.42
Chemotherapy 225 (49%) 200 (68%) 25 (15%) 0.003
*All patients who had total pancreatectomy/enucleation were excluded from mean operative time analysis; **PC- Packed cells.
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variable analysis identified age 70 years or older, tumor
diameter larger than 3 cm, positive microscopic margins,
poorly differentiated histology, and lymphatic metastasis
emerged as significant predictors of decreased DSS.
In the multivariable analysis, age ≥ 70 years (hazard
ratio [HR] = 1.64; 95% CI:1.16-3.45), tumor size ≥ 3c m
(HR = 1.42; 95% CI:1.21-2.87), poorly differentiated his-
tology (HR = 1.87; 95% CI:1.07-3.19), and lymphatic
metastasis (HR = 2.13; 95% CI:1.48-3.6) remained inde-
pendent prognosticators of adverse outcome (Table 3).
Intergroup age-related comparisons
Next, we analyzed a cohort of 460 patients who had sur-
gery for pancreatic neoplasm at our institution between
1995-2007 trying to identify clinical, pathological, treat-
ment, and outcome differences between two patient
sub-groups of age, ≥70 years (n = 166) vs. <70 years
(n = 294; Table 1).
Comparing patients characteristics, gender, incidence
of associated comorbidities, and jaundice at the time of
diagnosis differed significantly between the two age
groups (Table 1); 64 patients (39%) aged 70 years
or older were men vs. 150 (51%) in the younger cohort
(p = 0.01). 120 patients ≥70 years (72%) had associated
comorbidities vs. 126 (43%) patients <70 years (p =
0.002). Jaundice, as a presenting sign, was more common
in the older subset of patients, 46% (n = 77) vs. 28% (n =
83) in the younger group (p < 0.0001). Comparing tumor
characteristics, pancreatich e a dl o c a t i o nw a sm o r ec o m -
mon in patients ≥70 years, 72% (n = 120) vs. 59% (n =
173) in patients younger than 70 years (p = 0.004).
A higher rate of malignant histologies was identified in
patients aged 70 years or older vs. patients younger than
70 years; 73% (n = 121) vs. 59% (n = 173; p = 0.002),
respectively. Neuroendocrine tumors were less frequent
in elderly patients 3% (n = 5) vs. 10% (n = 28) in the
younger cohort (p = 0.009). Among adenocarcinoma
patients tumor size, its differentiation, and lymph node
involvement were comparable between the two groups.
Pre-operative workup did not significantly differ
between the two sub-cohorts; these include abdominal
CT which was performed in more than 95% in both
groups, EUS and EUS guided biopsy/FNA, and ERCP
(Table 1). Comparison of treatment variables demon-
s t r a t e dt h a tt h er a t eo fe l d e rly patients treated with
adjuvant chemotherapy was lower in comparison to the
younger sub-cohort; 15% vs. 68%, respectively (p =
0.003). No other significant treatment differences were
identified; nevertheless, comparing patients who under-
went PD, there was a trend towards a prolonged mean
operative time among the elderly vs. the younger age
group, 318 (SE:67) minutes vs. 268 minutes (SE:55),
respectively (p = 0.07). Estimated mean intra-operative
blood loss did not differ.
Outcomes characteristics are depicted in Table 4. Since
most elderly patients underwent PD, which is considered
Figure 1 Kaplan-Meier curves for disease-specific survival for the whole cohort of elderly patients (A), and for ductal adenocarcinoma
elderly patients stratified for ductal adenocarcinoma patients aged <70 years (blue line) versus ≥70 years (B).
Table 3 Multivariable Cox proportional hazards models
for pancreatic ductal adenocarcinoma- specific survival
Variable Levels HR (95% CI)
Age ≥70 years vs. <70 years 1.64 (1.16-3.45)
Tumor size >3 cm vs. ≤3 cm 1.42 (1.21-2.87)
Differentiation Poorly vs. well 1.87 (1.07-3.19)
Lymphatic metastasis Positive vs. negative 2.13 (1.48-3.61)
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post-operative outcome for this sub-cohort of patients
(n = 293). Mean post-operative length of stay was 28.2
days in the group of patients older than 70 years (range,
10-63) vs. 19.7 (range, 7-55) days in the younger age
cohort of patients (p < 0.0001). The incidence of post-
operative complications in patients older than 70 years
was 41% vs. 29% in patients younger than 70 years (p =
0.01). Septic complications and renal failure, in particu-
lar, were more common in patients older than 70 years,
31% vs. 21% (p = 0.02), and 8% vs. 1.5% (p < 0.0001) in
the younger cohort, respectively. Pancreatic fistula
o c c u r r e di n1 2( 2 0 % )v s .2 0( 8 % )p a t i e n t sa g e d7 0y e a r s
or older vs. patients younger than 70 years, respectively
(p = 0.12). Post-operative mortality, defined as death
within 30 days from surgery, was higher in the elderly
population, 5.8% (n = 7) vs. 2.3% (n = 4) in patients
≥70 years vs. < 70 years, respectively (p = 0.02).
Kaplan-Meier survival analysis compared outcomes of
ductal adenocarcinoma patients aged <70 years vs. ≥70
years. As depicted in Figure 1C patients aged 70 years
or older had a lower median DSS in comparison to the
younger cohort: 15 months (95% CI: 12.5-26.5) vs.
20 months (95% CI: 16.1-38.3), respectively (p = 0.05).
The estimated 1-, 2-, and 5-year DSS rates were 58%
(SE: 3.1), 36% (SE: 3.6), and 23% (SE: 3.7) vs. 73% (SE:
4.8), 45% (SE: 4.2), and 27% (SE: 1.9) in the older cohort
vs. the younger cohort, respectively.
Discussion
Pancreatic surgery carries relatively high postoperative
morbidity and long term outcomes for pancreatic cancer
patients are relatively modest, yet complete resection for
selected patients is the only curative therapeutic option.
Nevertheless, well known increased risk for intra- and/
or post-operative complications in the aged patients
may create a dilemma for both the surgeon and the
patient. Notwithstanding, a recent report showed that
surgery is avoided in most patients diagnosed with
resectable pancreatic neoplasm [19]. Another reported
series demonstrated that due to age-based decisions
elderly patients often receive less aggressive surgery, if
any, as well as less systemic chemotherapy. Taken
together these data, it is possible that age per-se plays a
role in denying surgery from older patients diagnosed
with resectable pancreatic malignancies; evidently such
treatment patterns may result in inferior outcomes
[20-24].
Most pancreatic tumors occur within the sixth or the
seventh decade of life; however, a large proportion of
patients are older [25,26]. Out of 460 evaluable patients
with pancreatic neoplasm who had complete macro-
scopic resection at our institution over the last decade,
36% (n = 166) were older than 70 and 15.8% (n = 73)
were 75 years or older. Moreover, the portion of
patients aged 70 or more who had pancreatic surgery at
our institution over the last decade has increased from
18% in 1996-2001 to 32.8% in 2002-2007. While this
trend may simply reflect demographic changes (aging)
in the population, it may also result from an increasing
awareness that major surgical procedures can be per-
formed safely in the elderly population in spite of signif-
icant comorbidities and/or reduced “physiological
reserves” as compared to younger patients [9].
Table 4 Outcomes characteristics
All patients
N = 460
<70 years
N = 294
≥70 years
N = 166
P value
Mean hospital stay (days)
Overall 18.6 (SE:17.5) 16.8 (SE:12.1) 26.2 (SE:16.4) <0.0001
PD* 23 (SE:18.1) 19.7 (SE:14.8) 28.2 (SE:15.3) <0.0001
Postoperative mortality (30 days)
Overall 13 (2.8%) 4 (1.4%) 9 (5.4%) 0.05
PD* 11 (3.7%) 4 (2.3%) 7 (5.8%) 0.02
Postoperative (PD*) complications
Overall 153 (33%) 85 (29%) 68 (41%) 0.01
Septic 115 (25%) 63 (21%) 52(31%) 0.02
Pancreatic fistula 44 (10%) 24 (8%) 20 (12%) 0.12
Bleeding 26 (6%) 15 (5%) 11 (7%) 0.28
Renal failure 18 (6%) 4 (1.5%) 14 (8%) <0.0001
Reoperation 29 (6%) 19 (7%) 10 (6%) 0.3
*The cohort of PD patients included 293 patients; 173 aged <70 years, 120 ≥70 years.
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ity and mortality risks following pancreatic surgery in
older patients [15,27-29]; bathe et al [28] have shown an
increased risk for immediate postoperative mortality
(within 30 days) in patients older than 75 years, whereas
Muscari and Riall [15,28] have demonstrated increased
overall complications rate in pancreatic cancer octogen-
arians. The median age for the present elderly cohort
was 75 years (range, 70-87) and more than half of the
patients had ASA scores ≥ 3. Nevertheless, our data
demonstrate that early postoperative outcomes for
patients older than 70 years are comparable to pre-
viously published younger cohorts, which has also been
reported by others [6,13,14,30,31]. Indeed, perioperative
mortality rate was higher among elderly patients, 5.8%
vs. 2.3% in the younger cohort; however, we find this
rate acceptable considering the scale of the operation
and the expected natural history of the disease without
surgery. About 40% of the older patients cohort experi-
enced postoperative complications; most of them fully
recovered following conservative treatment.
As for long-term postoperative results, in a recent
report, Riediger et al have shown that age was not an
independent risk factor for pancreatic cancer-specific
mortality when included in a multivariable Cox regres-
s i o na n a l y s i s[ 3 2 ] .T h i sd a t as u p p o r t sp r e v i o u sf i n d i n g s
reported by Fong, Richter, and others [13,33]. The cur-
rent report with a five-year ductal adenocarcinoma-
specific survival rate of 22% is similar to previous
analyses including patients of all ages who underwent
surgery for pancreatic adenocarcinoma in high volume
centers [4,6,13,34]. Nevertheless, our data analysis iden-
tified age ≥70 years as an independent adverse prognos-
tic factor for adenocarcinoma-specific survival with a
hazard ratio of 1.64 (1.16-3.45).
Comparing the older group of patients (≥70 years) to the
younger cohort, we found that older patients had a higher
rate of malignant pathologies; this could be explained by
selection bias rather than reflecting age-dependent biologi-
cal differences. Adenocarcinoma histology, tumor size and
grade were comparable, whereas pancreatic head tumors
were more common in older patients. This may explain
the higher incidence of jaundice as a presenting symptom
among older patients. Interestingly, the rate of jaundice
among the sub-group of patients who had PD for adeno-
carcinoma was higher among elderly individuals suggest-
ing a more complex physiological explanation (20% vs.
35%; p = 0.001) attributed to a decreased functional
reserve of the liver among these patients.
Adjuvant chemotherapy was significantly less frequently
administered in the older as compared to the younger
cohort (p = 0.003). In addition to various possible biologi-
cal differences which may shorten the survival of elderly
patients treated for pancreatic ductal adenocarcinoma less
use of systemic therapy may also contribute to the higher
rates of disease-specific mortality observed in these
patients. While our data demonstrate that pancreatic
cancer patients 70 years or older exhibit a lower five-year
DSS compared to younger patients, it is pertinent that
even in this age subset more than one third of the patients
survived two years and 20% 5 years or more when treated
with surgery. Taken together, these data, coupled with the
acceptable rates of post operative morbidity, the equiva-
lently low rates of post-operative mortality, and a reason-
able length of hospital stay suggest that pancreatic surgery
can be performed safely in older patients. This should
encourage clinicians not to deny pancreatic resection from
elderly patients, particularly those diagnosed with cancer.
Comprehensive pre-operative assessment of surgical risks,
careful pre-operative assessment, utilization of post-
operative intensive care units, and rehabilitation services
as needed are relevant to reducing overall peri-operative
morbidity and mortality.
In summary, previous data suggest that elderly
pancreatic cancer patients have worse outcomes; co-
morbidities and decreased physiological reserves have
historically reduced the enthusiasm of surgeons and
oncologists to operate on these patients. Our analysis of
retrospectively collected data from a single institution
demonstrates that surgical resection of pancreatic neo-
plasms in the elderly can usually be performed safely
with possible long term survival.
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